Do Natalie T, Phiri Kelesitse, Bussmann Hermann, Gaolathe Tendani, Marlink Richard G, Wester C William
Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP), Gaborone, Botswana.
AIDS Res Hum Retroviruses. 2010 Jun;26(6):685-91. doi: 10.1089/aid.2009.0222.
As increasing numbers of persons are placed on potentially life-saving combination antiretroviral therapy (cART) in sub-Saharan Africa, it is imperative to identify the psychosocial and social factors that may influence antiretroviral (ARV) medication adherence. Using an 87 question survey, the following data were collected from patients on cART in Botswana: demographics, performance (Karnofsky) score, perceived stigma and level of HIV disclosure, attitudes and beliefs concerning HIV/AIDS, substance and/or drug use, depression, and pharmacy and healthcare provider-related factors. Overall adherence rates were determined by patient self-report, institutional adherence, and a culturally modified Morisky scale. Three hundred adult patients were recruited between April and May 2005. The overall cART adherence rate was 81.3% based on 4 day and 1 month patient recall and on clinic attendance for ARV medication refills during the previous 3 months. Adults receiving cART for 1-6 months were the least adherent (77%) followed by those receiving cART for greater than 12 months (79%). Alcohol use, depression, and nondisclosure of positive HIV status to their partner were predictive of poor adherence rates (p value <0.02). A significant proportion (81.3%) of cART-treated adults were adherent to their prescribed treatment, with rates superior to those reported in resource-rich settings. Adherence rates were poorest among those just starting cART, most likely due to the presence of ARV-related toxicity. Adherence was lower among those who have been treated for longer periods of time (greater than 1 year), suggesting complacency, which may become a significant problem, especially among these long-term cART-treated patients who return to improved physical and mental functioning and may be less motivated to adhere to their ARV medications. Healthcare providers should encourage HIV disclosure to "at-risk" partners and provide ongoing counseling and education to help patients recognize and overcome HIV-associated stigma, alcohol abuse, and depression.
随着撒哈拉以南非洲地区越来越多的人开始接受具有潜在救命作用的抗逆转录病毒联合疗法(cART),识别可能影响抗逆转录病毒(ARV)药物依从性的心理社会和社会因素变得至关重要。通过一项包含87个问题的调查,从博茨瓦纳接受cART治疗的患者中收集了以下数据:人口统计学信息、表现(卡诺夫斯基)评分、感知到的耻辱感和HIV披露水平、对HIV/AIDS的态度和信念、物质和/或药物使用情况、抑郁情况以及与药房和医疗保健提供者相关的因素。总体依从率通过患者自我报告、机构依从性以及经过文化修改的莫利斯基量表来确定。2005年4月至5月期间招募了300名成年患者。根据患者4天和1个月的回忆以及前3个月抗逆转录病毒药物补充的门诊就诊情况,总体cART依从率为81.3%。接受cART治疗1至6个月的成年人依从性最差(77%),其次是接受cART治疗超过12个月的成年人(79%)。饮酒、抑郁以及未向伴侣披露HIV阳性状态可预测依从率较低(p值<0.02)。接受cART治疗的成年人中有很大一部分(81.3%)坚持按规定治疗,其依从率高于资源丰富地区报告的依从率。刚开始接受cART治疗的患者依从率最差,很可能是由于存在与抗逆转录病毒药物相关的毒性。接受治疗时间较长(超过1年)的患者依从性较低,这表明自满情绪可能成为一个重大问题,尤其是在这些长期接受cART治疗且身体和心理功能有所改善但可能坚持服用抗逆转录病毒药物动力较小的患者中。医疗保健提供者应鼓励向“高危”伴侣披露HIV情况,并提供持续的咨询和教育,以帮助患者认识并克服与HIV相关的耻辱感、酒精滥用和抑郁。